BioSpace News Archive

FDA

FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab).

April 19, 2023

·

15 min read

Press Releases

Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced data from four presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

April 19, 2023

·

9 min read

Biotech Bay

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 19, 2023

Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 11,035 shares of common stock of the company and 17,710 restricted stock units of the company’s common stock to 11 newly hired non-executive officers of the company.

April 19, 2023

·

2 min read

Business

ATEC Acquires Navigation-Enabled Robotics Platform; Raises 2023 Revenue Guidance on Strength of Preliminary First Quarter Revenue Results

Alphatec Holdings, Inc. announced that it has acquired all assets related to the REMI Robotic Navigation System from Fusion Robotics, LLC, a privately held medical technology company, for a purchase price of $55 million.

April 19, 2023

·

8 min read

Business

Personalis to Announce First Quarter 2023 Financial Results

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023.

April 19, 2023

·

1 min read

BioMidwest

Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement

Athersys, Inc. announced that it has closed its previously announced offering to sell 3,685,000 shares of the Company’s common stock in a registered direct offering and warrants to purchase 3,685,000 Shares at a purchase price per Share of $1.00 in a concurrent private placement.

April 19, 2023

·

3 min read

Biotech Bay

Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting

Circle Pharma announced that two poster presentations at the American Association for Cancer Research Annual Meeting held April 14-19, in Orlando, Florida, highlight promising pre-clinical data of its first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors targeting intractable cancers.

April 19, 2023

·

3 min read

Pharm Country

PANTHERx® Rare Announces Release of CUVRIOR™ (trientine tetrahydrochloride) to Treat Wilson Disease

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of CUVRIOR to treat stable Wilson Disease in adults who are de-coppered and able to take penicillamine.

April 19, 2023

·

4 min read

Policy

InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL

InnoCare Pharma, a leading biopharmaceutical company, announced that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration in the treatment of patients with relapsed/refractory marginal zone lymphoma.

April 19, 2023

·

4 min read

Business

Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023

Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results after market close on Wednesday, May 3, 2023.

April 19, 2023

·

1 min read